Fidelity Investments
PCVX icon

Fidelity Investments’s Vaxcyte PCVX Stock Holding History

Fidelity Investments’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.21B Buy
20,852,907
+4,360,046
+26% +$237M 0.05% 270
2026
Q1 		$958M Buy
16,492,861
+2,658,347
+19% +$144M 0.05% 311
2025
Q4 		$638M Buy
13,834,514
+1,324,581
+11% +$59.2M 0.03% 425
2025
Q3 		$451M Buy
12,509,933
+358,883
+3% +$11.9M 0.02% 544
2025
Q2 		$395M Sell
12,151,050
-361,184
-3% -$11.8M 0.02% 579
2025
Q1 		$472M Sell
12,512,234
-579,414
-4% -$46.3M 0.03% 475
2024
Q4 		$1.07B Sell
13,091,648
-2,709,019
-17% -$269M 0.06% 247
2024
Q3 		$1.81B Sell
15,800,667
-366,673
-2% -$33M 0.11% 149
2024
Q2 		$1.22B Sell
16,167,340
-93,819
-0.6% -$6.39M 0.08% 203
2024
Q1 		$1.11B Buy
16,261,159
+2,047,794
+14% +$142M 0.07% 232
2023
Q4 		$893M Buy
14,213,365
+136,328
+1% +$7.08M 0.07% 255
2023
Q3 		$718M Buy
14,077,037
+20,801
+0.1% +$1.03M 0.06% 285
2023
Q2 		$702M Buy
14,056,236
+2,247,671
+19% +$107M 0.06% 312
2023
Q1 		$443M Buy
11,808,565
+1,639,283
+16% +$69.5M 0.04% 449
2022
Q4 		$488M Buy
10,169,282
+1,272,085
+14% +$49.9M 0.05% 401
2022
Q3 		$214M Buy
8,897,197
+383,791
+5% +$9.73M 0.02% 635
2022
Q2 		$185M Buy
8,513,406
+136,464
+2% +$3.16M 0.02% 720
2022
Q1 		$202M Buy
8,376,942
+502,592
+6% +$11M 0.02% 769
2021
Q4 		$187M Buy
7,874,350
+45,965
+0.6% +$1.07M 0.01% 828
2021
Q3 		$199M Buy
7,828,385
+121,576
+2% +$2.95M 0.02% 812
2021
Q2 		$173M Buy
7,706,809
+7,666
+0.1% +$157K 0.01% 877
2021
Q1 		$152M Buy
7,699,143
+56,738
+0.7% +$1.43M 0.01% 903
2020
Q4 		$203M Buy
7,642,405
+1,266,642
+20% +$47.1M 0.02% 742
2020
Q3 		$315M Buy
6,375,763
+1,669,004
+35% +$66.5M 0.03% 455
2020
Q2 		$149M Buy
+4,706,759
New +$151M 0.02% 719

Other funds holding PCVX

JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's PCVX Position: Q2 2026 in Review

Fidelity Investments increased its Vaxcyte (PCVX) stake by 26% in Q2 2026, buying an estimated $237M and bringing the position to 20,852,907 shares worth $1.21B. The position accounts for 0.05% of the portfolio, ranked #270.

Fidelity Investments first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $1.81B in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Fidelity Investments held 20,852,907 shares of Vaxcyte worth $1.21B as of Q2 2026.
  • Fidelity Investments bought 4,360,046 Vaxcyte shares in Q2 2026, an estimated $237M.
  • Vaxcyte made up 0.05% of Fidelity Investments's portfolio in Q2 2026, its #270 holding.
  • Fidelity Investments first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • Fidelity Investments's Vaxcyte position peaked at $1.81B in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.